Elevated C-reactive Protein Levels Independently Predict the Development of Prediabetes Markers in Subjects with Normal Glucose Regulation

Abstract

Aims Prediabetes is a precursor of diabetes and increases the risk of cardiovascular disease. Individuals with prediabetes reportedly have higher C-reactive protein levels, which is a risk factor for diabetes, relative to individuals with normal glucose regulation. Inflammation may play a role in the very early-phase deterioration of glucose metabolism, although there is insufficient knowledge regarding this relationship. Thus, we examined the association between serum C-reactive protein level and the development of three prediabetes markers.

Methods This study included 743 subjects with normal glucose regulation at baseline who completed oral glucose tolerance tests at baseline and after approximately 5 years. Subjects with a history of cardiovascular disease were excluded.

Results During the 5-year follow-up, 55 subjects developed isolated impaired glucose tolerance (IGT; 2h-plasma glucose levels of 7.8–11.0 mmol/L), 24 subjects developed isolated impaired fasting glucose (IFG; fasting plasma glucose levels of 6.1–7.0 mmol/L), 3 subjects developed IFG plus IGT, and 53 subjects developed isolated elevated glycated hemoglobin levels (HbA1c; level of 41–47 mmol/mol). The multivariate analysis revealed that, relative to the lowest quartile, the highest serum C-reactive protein quartile was independently associated with an increased risk of developing isolated elevated HbA1c levels (odds ratio: 2.95, 95% confidence interval: 1.16–7.51, P=0.024) and marginally associated with an increased risk of developing impaired glucose tolerance plus diabetes. However, C-reactive protein levels were not associated with an increased risk of developing IFG.

Conclusions Elevated serum C-reactive protein levels independently predicted elevated HbA1c levels, but not IFG.

Key words

inflammation - impaired glucose tolerance - impaired fasting glucose

Publication History

Received: 19 November 2018
Received: 27 February 2019

Accepted: 04 March 2019

Article published online:
08 April 2019

• References

• 1 Smith NL, Barzilay JI, Shaffer D. et al. Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: The Cardiovascular Health Study. Archives of internal medicine 2002; 162: 209-216
• 2 [Anonymous]. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Archives of internal medicine 2001; 161: 397-405
• 3 Huang Y, Cai X, Mai W. et al. Association between prediabetes and risk of cardiovascular disease and all cause mortality: Systematic review and meta-analysis. BMJ 2016; 355: i5953. DOI: 10.1136/bmj.i5953.
• 4 Pradhan AD, Manson JE, Rifai N. et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama 2001; 286: 327-334
• 5 Barzilay JI, Abraham L, Heckbert SR. et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: The Cardiovascular Health Study. Diabetes 2001; 50: 2384-2389
• 6 Wang C, Yatsuya H, Tamakoshi K. et al. Positive association between high-sensitivity C-reactive protein and incidence of type 2 diabetes mellitus in Japanese workers: 6-year follow-up. Diabetes / metabolism research and reviews 2013; 29: 398-405 DOI: 10.1002/dmrr.2406.
• 7 Wang X, Bao W, Liu J. et al. Inflammatory markers and risk of type 2 diabetes: A systematic review and meta-analysis. Diabetes care 2013; 36: 166-175 DOI: 10.2337/dc12-0702.
• 8 Kato K, Otsuka T, Saiki Y. et al. Association between elevated c-reactive protein levels and prediabetes in adults, particularly impaired glucose tolerance. Canadian journal of diabetes 2018; DOI: 10.1016/j.jcjd.2018.03.007.
• 9 Festa A, D'Agostino Jr. R, Tracy RP. et al. C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects; the Insulin Resistance Atherosclerosis Study. Diabetic medicine: A journal of the British Diabetic Association 2002; 19: 939-943
• 10 Guerrero-Romero F, Simental-Mendia LE, Rodriguez-Moran M. Association of C-reactive protein levels with fasting and postload glucose levels according to glucose tolerance status. Archives of medical research 2014; 45: 70-75 DOI: 10.1016/j.arcmed.2013.11.004.
• 11 Jaiswal A, Tabassum R, Podder A. et al. Elevated level of C-reactive protein is associated with risk of prediabetes in Indians. Atherosclerosis 2012; 222: 495-501 DOI: 10.1016/j.atherosclerosis.2012.02.034.
• 12 Myers GL, Rifai N, Tracy RP. et al. CDC / AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group. Circulation 2004; 110: e545-e549 DOI: 10.1161/01.CIR.0000148980.87579.5E.
• 13 Pearson TA, Mensah GA, Alexander RW. et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511
• 14 Kashiwagi A, Kasuga M, Araki E. et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Journal of diabetes investigation 2012; 3: 39-40 DOI: 10.1111/j.2040-1124.2012.00207.x.
• 15 WHO. Definition and Diagnisis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO / IDF Consultation. Geneva: World Health Organization; 2006
• 16 WHO. Use of Glycated Haemoglobin (HbA1c) in the diagnosis of Diabetes Mellitus: Abbrevated Report of a WHO / IDF Consultation. Geneva: World Health Organization; 2011
• 17 Chatterton H, Younger T, Fischer A. et al. Risk identification and interventions to prevent type 2 diabetes in adults at high risk: Summary of NICE guidance. BMJ 2012; 345: e4624. DOI: 10.1136/bmj.e4624.
• 18 [Anonymous]. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes care 2009; 32: 1327-1334 DOI: 10.2337/dc09-9033.
• 19 Ong KL, Tso AW, Xu A. et al. Evaluation of the combined use of adiponectin and C-reactive protein levels as biomarkers for predicting the deterioration in glycaemia after a median of 5.4 years. Diabetologia 2011; 54: 2552-2560 DOI: 10.1007/s00125-011-2227-0.
• 20 Tan KC, Wat NM, Tam SC. et al. C-reactive protein predicts the deterioration of glycemia in chinese subjects with impaired glucose tolerance. Diabetes care 2003; 26: 2323-2328
• 21 Outline of the National Health and Nutrition Survey (NHNS) Japan, 2012. [(accessed on 21 Feburary 2019)]; Available online
• 22 Kubota Y, Iso H, Tamakoshi A. Association of Body Mass Index and Mortality in Japanese Diabetic Men and Women Based on Self-Reports: The Japan Collaborative Cohort (JACC) Study. Journal of epidemiology 2015; 25: 553-558 DOI: 10.2188/jea.JE20150011.
• 23 Stefan N, Schick F, Haring HU. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell metabolism 2017; 26: 292-300 DOI: 10.1016/j.cmet.2017.07.008.
• 24 Abdul-Ghani MA, Jenkinson CP, Richardson DK. et al. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: Results from the Veterans Administration Genetic Epidemiology Study. Diabetes 2006; 55: 1430-1435
• 25 Meyer C, Pimenta W, Woerle HJ. et al. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes care 2006; 29: 1909-1914 DOI: 10.2337/dc06-0438.
• 26 Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795 DOI: 10.2337/db09-9028.
• 27 Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. The Journal of clinical investigation 2006; 116: 1793-1801 DOI: 10.1172/JCI29069.
• 28 Festa A, D'Agostino Jr. R, Howard G. et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47
• 29 Feinstein R, Kanety H, Papa MZ. et al. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. The Journal of biological chemistry 1993; 268: 26055-26058
• 30 Plomgaard P, Bouzakri K, Krogh-Madsen R. et al. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005; 54: 2939-2945
• 31 Buysschaert M, Medina JL, Bergman M. et al. Prediabetes and associated disorders. Endocrine 2015; 48: 371-393 DOI: 10.1007/s12020-014-0436-2.
• 32 Cardellini M, Andreozzi F, Laratta E. et al. Plasma interleukin-6 levels are increased in subjects with impaired glucose tolerance but not in those with impaired fasting glucose in a cohort of Italian Caucasians. Diabetes / metabolism research and reviews 2007; 23: 141-145 DOI: 10.1002/dmrr.679.
• 33 Stefan N, Fritsche A, Schick F. et al. Phenotypes of prediabetes and stratification of cardiometabolic risk. The lancet Diabetes & endocrinology 2016; 4: 789-798 DOI: 10.1016/S2213-8587(16)00082-6.